Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 3,4-dihydro-3-(methyl-d3)-4-oxo-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C6H3D3N6O2
Formula Weight: 197.2
CAS Number: 208107-14-6
Notes: Temozolomide-d3 is intended for use as an internal standard for the quantification of temozolomide (Item No. 14163) by GC- or LC-MS. Temozolomide is a prodrug form of the DNA alkylating agent MTIC (Item No. 18863).{39896} It is converted to MTIC in a non-enzymatic manner under physiological conditions. Temozolomide is selectively cytotoxic to U87 and D54 glioblastoma cells, which do not express O6-methylguanine-DNA methyltransferase (MGMT), over MGMT-expressing T98G and U3054MG glioblastoma cells (IC50s = 51, 12, 660, and 370 µM, respectively).{42788} It increases survival in a Br23c glioblastoma orthotopic mouse xenograft model when administered at a dose of 15 mg/kg. Temozolomide, in combination with antibodies targeting CD47, decreases tumor volume and increases the number of tumor-infiltrating CD4+ and CD8+ T cells in a GL261 murine glioma model.{65554} Formulations containing temozolomide have been used in the treatment of glioblastoma multiforme (GBM) and refractory anaplastic astrocytoma.
English
Deutsch
